Previous 10 | Next 10 |
Neoleukin is a leader in de novo drug design. The company's lead asset was recently put on clinical hold, pending more dosing data, creating a window to buy the stock. The company has the platform potential to expand their pipeline to a wide-range of protein therapeutics for cancer an...
The following slide deck was published by Relay Therapeutics, Inc. in conjunction with this event. For further details see: Relay Therapeutics (RLAY) Presents At 39th Annual J.P. Morgan Healthcare Conference - Slideshow
CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 4:30 p.m. ET. The presentation will be webcast live and may be accessed from the Investor ...
Relay Therapeutics (RLAY) has signed a worldwide license and collaboration agreement with Genentech, a member of the Roche Group, for the development and commercialization of RLY-1971, a potent inhibitor of SHP2 to expand into multiple combination studies including with Genentech’s inv...
Collaboration brings together clinical stage SHP2 and KRAS G12C inhibitors Relay Therapeutics will receive $75 million upfront and is eligible to receive an additional $25 million in near-term payments and $695 million in additional potential milestones, plus royalties on ...
Kinnate Biopharma (KNTE) has raised the proposed deal size for its upcoming IPO.The company now plans to raise $213M by offering 11.5M shares at a price range of $18 to $19 vs. original offering of 10M shares at a range of $16 to $18.Kinnate is focused on the discovery and development of...
Kinnate Biopharma aims to raise $170 million in an IPO. The firm is developing kinase inhibitor-based treatment candidates for various cancers. KNTE has produced promising results in preclinical studies, but is still extremely high risk; the IPO may be more suited to long-term hol...
Relay Therapeutics (RLAY): Q3 GAAP EPS of -$3.00.Cash, cash equivalents and investments of $713M. Press Release For further details see: Relay Therapeutics reports Q3 results
CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparalleled insights into protein motion, today reported third quarter 2020 financial results. ...
Four not-widely-followed biotech stocks were pitched at the recent Ira Sohn conference. Below is the full audio of the pitches, and a list of the publicly-traded landscape for each. For further details see: These Are The Four Biotech Stocks Recently Pitched At The Ira Sohn Conference
News, Short Squeeze, Breakout and More Instantly...
Relay Therapeutics Inc. Company Name:
RLAY Stock Symbol:
NASDAQ Market:
2024-05-10 16:30:03 ET Oppenheimer analyst issues MARKET OUTPERFORM recommendation for RLAY on May 10, 2024 02:00PM ET. The previous analyst recommendation was Market Outperform. RLAY was trading at $6.425 at issue of the analyst recommendation. The overall analyst conse...
2024-05-06 09:15:03 ET Oppenheimer analyst issues OUTPERFORM recommendation for RLAY on May 6, 2024 07:53AM ET. The previous analyst recommendation was Outperform. RLAY was trading at $7.04 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported first quarter 2024 financia...